BHVN
NYSE · Biotechnology
Biohaven Ltd
$9.63
+0.04 (+0.42%)
Open$9.70
Previous Close$9.59
Day High$9.89
Day Low$9.52
52W High$22.05
52W Low$7.48
Volume—
Avg Volume1.82M
Market Cap1.47B
P/E Ratio—
EPS$-6.96
SectorBiotechnology
Analyst Ratings
Strong Buy
25 analysts
Price Target
+212.1% upside
Current
$9.63
$9.63
Target
$30.06
$30.06
$17.22
$30.06 avg
$35.82
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 166.56M | 159.79M | 165.80M |
| Net Income | 26.40M | 27.52M | 28.79M |
| Profit Margin | 15.9% | 17.2% | 17.4% |
| EBITDA | 53.49M | 47.96M | 56.14M |
| Free Cash Flow | 17.32M | 22.87M | 17.57M |
| Rev Growth | +0.5% | -2.4% | +23.6% |
| Debt/Equity | 0.62 | 0.47 | 0.55 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |